Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion

Ryo Ohtani, Hidekazu Tomimoto, Hideaki Wakita, Hiroshi Kitaguchi, Kayoko Nakaji, Ryosuke Takahashi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

S100 protein is expressed primarily by astroglia in the brain, and accumulates in and around the ischemic lesions. Arundic acid, a novel astroglia-modulating agent, is neuroprotective in acute cerebral infarction, whereas the protective effects remain unknown during chronic cerebral hypoperfusion. Rats undergoing chronic cerebral hypoperfusion were subjected to a bilateral ligation of the common carotid arteries, and were allowed to survive for 3, 7 and 14 days. The animals received a daily intraperitoneal injection of 5.0, 10.0 or 20.0 mg/kg of arundic acid, or vehicle, for 14 days. Alternatively, other groups of rats received a delayed intraperitoneal injection of 20.0 mg/kg of arundic acid or vehicle, which started from 1, 3 or 7 days after ligation and continued to 14 days. The degree of white matter (WM) lesions and the numerical density of S100 protein-immunoreactive astroglia were estimated. In the WM of rats with vehicle injections, the number of S100 protein-immunoreactive astroglia increased significantly after chronic cerebral hypoperfusion as compared to the sham-operation. A dosage of 10.0 and 20.0 mg/kg of arundic acid suppressed the numerical increase in S100 protein-immunoreactive astroglia and the WM lesions. These pathological changes were suppressed with delayed treatment up to 7 days in terms of astroglial activation, and up to 3 days in terms of the WM lesions. The protective effects of arundic acid against WM lesions were demonstrated in a dose-dependent manner, and even after postischemic treatments. These results suggest the potential usefulness of arundic acid in the treatment of cerebrovascular WM lesions.

Original languageEnglish
Pages (from-to)195-200
Number of pages6
JournalBrain Research
Volume1135
Issue number1
DOIs
Publication statusPublished - 02-03-2007

Fingerprint

S100 Proteins
Astrocytes
Brain
Intraperitoneal Injections
Ligation
Common Carotid Artery
Cerebral Infarction
Neuroprotective Agents
ONO2506
White Matter
Therapeutics
Injections

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Ohtani, Ryo ; Tomimoto, Hidekazu ; Wakita, Hideaki ; Kitaguchi, Hiroshi ; Nakaji, Kayoko ; Takahashi, Ryosuke. / Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. In: Brain Research. 2007 ; Vol. 1135, No. 1. pp. 195-200.
@article{97c7f4098d6649e9b83aca13a44f1760,
title = "Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion",
abstract = "S100 protein is expressed primarily by astroglia in the brain, and accumulates in and around the ischemic lesions. Arundic acid, a novel astroglia-modulating agent, is neuroprotective in acute cerebral infarction, whereas the protective effects remain unknown during chronic cerebral hypoperfusion. Rats undergoing chronic cerebral hypoperfusion were subjected to a bilateral ligation of the common carotid arteries, and were allowed to survive for 3, 7 and 14 days. The animals received a daily intraperitoneal injection of 5.0, 10.0 or 20.0 mg/kg of arundic acid, or vehicle, for 14 days. Alternatively, other groups of rats received a delayed intraperitoneal injection of 20.0 mg/kg of arundic acid or vehicle, which started from 1, 3 or 7 days after ligation and continued to 14 days. The degree of white matter (WM) lesions and the numerical density of S100 protein-immunoreactive astroglia were estimated. In the WM of rats with vehicle injections, the number of S100 protein-immunoreactive astroglia increased significantly after chronic cerebral hypoperfusion as compared to the sham-operation. A dosage of 10.0 and 20.0 mg/kg of arundic acid suppressed the numerical increase in S100 protein-immunoreactive astroglia and the WM lesions. These pathological changes were suppressed with delayed treatment up to 7 days in terms of astroglial activation, and up to 3 days in terms of the WM lesions. The protective effects of arundic acid against WM lesions were demonstrated in a dose-dependent manner, and even after postischemic treatments. These results suggest the potential usefulness of arundic acid in the treatment of cerebrovascular WM lesions.",
author = "Ryo Ohtani and Hidekazu Tomimoto and Hideaki Wakita and Hiroshi Kitaguchi and Kayoko Nakaji and Ryosuke Takahashi",
year = "2007",
month = "3",
day = "2",
doi = "10.1016/j.brainres.2006.11.084",
language = "English",
volume = "1135",
pages = "195--200",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. / Ohtani, Ryo; Tomimoto, Hidekazu; Wakita, Hideaki; Kitaguchi, Hiroshi; Nakaji, Kayoko; Takahashi, Ryosuke.

In: Brain Research, Vol. 1135, No. 1, 02.03.2007, p. 195-200.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion

AU - Ohtani, Ryo

AU - Tomimoto, Hidekazu

AU - Wakita, Hideaki

AU - Kitaguchi, Hiroshi

AU - Nakaji, Kayoko

AU - Takahashi, Ryosuke

PY - 2007/3/2

Y1 - 2007/3/2

N2 - S100 protein is expressed primarily by astroglia in the brain, and accumulates in and around the ischemic lesions. Arundic acid, a novel astroglia-modulating agent, is neuroprotective in acute cerebral infarction, whereas the protective effects remain unknown during chronic cerebral hypoperfusion. Rats undergoing chronic cerebral hypoperfusion were subjected to a bilateral ligation of the common carotid arteries, and were allowed to survive for 3, 7 and 14 days. The animals received a daily intraperitoneal injection of 5.0, 10.0 or 20.0 mg/kg of arundic acid, or vehicle, for 14 days. Alternatively, other groups of rats received a delayed intraperitoneal injection of 20.0 mg/kg of arundic acid or vehicle, which started from 1, 3 or 7 days after ligation and continued to 14 days. The degree of white matter (WM) lesions and the numerical density of S100 protein-immunoreactive astroglia were estimated. In the WM of rats with vehicle injections, the number of S100 protein-immunoreactive astroglia increased significantly after chronic cerebral hypoperfusion as compared to the sham-operation. A dosage of 10.0 and 20.0 mg/kg of arundic acid suppressed the numerical increase in S100 protein-immunoreactive astroglia and the WM lesions. These pathological changes were suppressed with delayed treatment up to 7 days in terms of astroglial activation, and up to 3 days in terms of the WM lesions. The protective effects of arundic acid against WM lesions were demonstrated in a dose-dependent manner, and even after postischemic treatments. These results suggest the potential usefulness of arundic acid in the treatment of cerebrovascular WM lesions.

AB - S100 protein is expressed primarily by astroglia in the brain, and accumulates in and around the ischemic lesions. Arundic acid, a novel astroglia-modulating agent, is neuroprotective in acute cerebral infarction, whereas the protective effects remain unknown during chronic cerebral hypoperfusion. Rats undergoing chronic cerebral hypoperfusion were subjected to a bilateral ligation of the common carotid arteries, and were allowed to survive for 3, 7 and 14 days. The animals received a daily intraperitoneal injection of 5.0, 10.0 or 20.0 mg/kg of arundic acid, or vehicle, for 14 days. Alternatively, other groups of rats received a delayed intraperitoneal injection of 20.0 mg/kg of arundic acid or vehicle, which started from 1, 3 or 7 days after ligation and continued to 14 days. The degree of white matter (WM) lesions and the numerical density of S100 protein-immunoreactive astroglia were estimated. In the WM of rats with vehicle injections, the number of S100 protein-immunoreactive astroglia increased significantly after chronic cerebral hypoperfusion as compared to the sham-operation. A dosage of 10.0 and 20.0 mg/kg of arundic acid suppressed the numerical increase in S100 protein-immunoreactive astroglia and the WM lesions. These pathological changes were suppressed with delayed treatment up to 7 days in terms of astroglial activation, and up to 3 days in terms of the WM lesions. The protective effects of arundic acid against WM lesions were demonstrated in a dose-dependent manner, and even after postischemic treatments. These results suggest the potential usefulness of arundic acid in the treatment of cerebrovascular WM lesions.

UR - http://www.scopus.com/inward/record.url?scp=33846641320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846641320&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2006.11.084

DO - 10.1016/j.brainres.2006.11.084

M3 - Article

C2 - 17210147

AN - SCOPUS:33846641320

VL - 1135

SP - 195

EP - 200

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -